• br Clinical realities br Commentary on uses of selective lya

  2024-06-18

  

  Clinical realities Commentary on uses of selective 17,20 lyase inhibitors If continued monitoring of these same parameters along with tracking of circulating ACTH in human trials confirms these new drugs are the long sought after 17,20 lyase inhibitors, then we may for the first time be able t

• br Experimental br Results and

  2024-06-18

  

  Experimental Results and discussion Conclusion Acknowledgments This work is supported by the National Basic Research Program of China (973 Program 2016YFA0201201 and 2013CB932702), a project funded by the Priority Academic Program Development of Jiangsu Higher Education Institutions (PAP

• The therapeutic potential of ML induced MET against cells

  2024-06-18

  

  The therapeutic potential of ML327-induced MET against cotransporter of mesenchymal origin has not been explored. In the present study, we hypothesized that induction of MET using ML327 would block the growth of ES cells and sensitize to TRAIL-mediated apoptosis. Herein, we report that ML327 induce

• Autocrine regulations of several adipokines e g leptin

  2024-06-18

  

  Autocrine regulations of several adipokines (e.g., leptin and resistin) on adipocytes have been reported (Karastergiou and Mohamed-Ali, 2010, Ye et al., 2010). Several lines of evidence have shown that apelin influences adipocyte functions, such as, lipolysis and glucose uptake (Dray et al., 2008, Y

• br Materials and methods br

  2024-06-18

  

  Materials and methods Results Discussion Pulmonary fibrosis is a progressive and chronic lung disease and its typical features include EGTA proliferation, epithelial injury, chronic interstitial inflammation, increased extracellular matrix (ECM) production, and collapse of alveoli, all of

• br Experimental section br Acknowledgment

  2024-06-18

  

  Experimental section Acknowledgment S.B.T. is grateful to the Deutsche Forschungsgemeinschaft (DFG), the Wilhelm Sander-Stiftung and Interdisciplinary Center for Molecular Materials (ICMM) for generous research support. M.M. greatly acknowledges the experimental support and the scientific cont

• br Introduction Sustained over activation of neurohormonal s

  2024-06-18

  

  Introduction Sustained over-activation of neurohormonal systems is a hallmark in the pathophysiology of cardiac dysfunction following myocardial infarction (MI) and heart failure (HF). Inhibitors of the renin-angiotensin enzyme used in the synthesis of mrna system (RAAS) constitute cornerstones

• Immunohistochemistry Hearts from young and aged

  2024-06-18

  

  Immunohistochemistry: Hearts from young and aged mice were collected at the indicated times, fixed overnight in 10% formalin, and embedded in paraffin. Serial 5-μm heart sections from each group were analyzed. Samples were stained with H&E for routine histologic examination. Immunohistochemical stai

• ACY-241 In conclusion we demonstrated that in the

  2024-06-18

  

  In conclusion, we demonstrated that, in the skeletal muscle of rats with T1DM, CRBN levels increased and AMPK, Akt, GLUT4, PGC-1α, and FNDC5 levels decreased, resulting in increased fasting glucose levels. Aerobic exercise training decreased levels of CRBN, which was possibly mediated by AMPK, Akt,

• Interestingly metabolic dysfunction is also observed in amyo

  2024-06-18

  

  Interestingly, metabolic dysfunction is also observed in amyotrophic lateral sclerosis (ALS). Patients and mouse models of familial ALS exhibit higher levels of resting Nitrotetrazolium Blue chloride mg expenditure and lower fat-free mass, indicating a hypermetabolic phenotype. Lim et al. (2012) fo

• Clinical observations of individuals with

  2024-06-18

  

  Clinical observations of individuals with a decrease in 12-LOX 5003 are consistent with 12-LOX potentiating platelet activation and thrombus formation [40]. However, the relative contribution of 12-LOX to these complex disorders cannot be fully elucidated in the absence of a biochemical assessment

• Rosiglitazone br Conflict of interest statement br Introduct

  2024-06-18

  

  Conflict of interest statement Introduction The global prevalence of Alzheimer's disease (AD) is expected to increase to 106 million in 2050 from 30 million in 2010 (Brookmeyer et al., 2007), which will further impose a significant economic burden on health systems and society as a whole (Broo

• The G R mutation is located at the solvent

  2024-06-18

  

  The G1202R mutation is located at the solvent front of the ALK kinase domain adjacent to the inhibitor's binding pocket. Although barely reported in the setting of crizotinib resistance, it has emerged as the most refractory mutation to both the first- and second-generation ALK inhibitors. The large

• Liao and van Linden et al

  2024-06-18

  

  Liao [47] and van Linden et al. [48] divided the gap between the N-terminal and C-terminal lobes into a front cleft or pocket, a gate area, and a back cleft. The back pocket corresponds to the gate area and the back cleft. The front cleft includes the Gly-rich loop, the hinge, the linker connecting

• This evidence suggests the strong clinical

  2024-06-18

  

  This evidence suggests the strong clinical relevance of the identification of acquired resistance mechanisms for a proper therapeutic decision in patients with ALK-rearranged NSCLC. When the tissue is not available, the analysis of circulating tumor DNA (cfDNA) can be a valid alternative for the det

15122 records 83/1009 page Previous Next First page 上5页 8182838485 下5页 Last page